Akebia Therapeutics, Inc. (AKBA)
$0.77-2.53%Close
SELLCRISIS · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $207M
- Beta
- 0.23
- P/E (TTM)
- -7.13
- Short % float
- 8.58%
- Days to cover
- 3.5
- SI change
- +9.6%
- 1W
- -12.50%
- 1M
- -19.79%
- vs SPY 1W
- -12.92%
- vs SPY 1M
- -21.85%
Industry peers
FMP comparable companies · ranked by market cap
- KALVKalVista Pharmaceuticals, Inc.$1.4B$27.00
- VTYXVentyx Biosciences, Inc.$1.0B$14.00
- RIGLBUYRigel Pharmaceuticals, Inc.$908MBULLQ 9$49.08-3.42%
- CRVSSELLCorvus Pharmaceuticals, Inc.$885MCRISISQ 13$10.52-6.37%
- FDMTSELL4D Molecular Therapeutics, Inc.$697MRECOVERYQ 4$13.33-4.92%
- OLMASELLOlema Pharmaceuticals, Inc.$683MCRISISQ -1$7.82-4.62%
- ZVRASELLZevra Therapeutics, Inc.$673MCRISISQ -7$11.39-8.22%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on AKBA?
- LOPJLB’s latest quantitative signal on Akebia Therapeutics, Inc. (AKBA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is AKBA in?
- Akebia Therapeutics, Inc. (AKBA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Akebia Therapeutics, Inc. (AKBA) do?
- Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney …